BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bioinformatics Software | QIAGEN Digital Insights - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://staging.digitalinsights.supremeclients.com
X-WR-CALDESC:Events for Bioinformatics Software | QIAGEN Digital Insights
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20240912T110000
DTEND;TZID=UTC:20240912T120000
DTSTAMP:20260505T164303
CREATED:20240821T173902Z
LAST-MODIFIED:20241024T183100Z
UID:10000796-1726138800-1726142400@staging.digitalinsights.supremeclients.com
SUMMARY:Expanding neoantigen discovery with COSMIC
DESCRIPTION:Neoantigens are among the newest promising targets for cancer treatment. Unlike tumor-associated antigens\, neoantigens are produced only by tumor cells. These unique molecular markers are highly visible to the immune system\, making them ideal for personalized immunotherapies. They may also be able to predict both tumor survival prognosis and immune checkpoint blockade responses. Neoantigens are presented by human leukocyte antigen class I molecules (HLA-I) to T cells\, providing an ideal pathway for detection by shotgun proteomics. To identify these elusive targets\, scientists often rely on whole exome sequencing (WES)-derived data. However\, this approach can miss rare or low-frequency mutations\, especially in cancers with a low tumor mutational burden (TMB). \nThe Catalogue of Somatic Mutations in Cancer (COSMIC) can bridge this gap by providing researchers with detailed information about somatic mutations in human cancer. Unlock the full potential of neoantigen-targeted therapies and enhance traditional approaches like WES with our comprehensive\, expert-curated knowledge base. \nIn this webinar\, we’ll learn to: \n\nUncover and validate potential neoantigens with a recent peer-reviewed study that uses COSMIC mutation data from human hepatocellular carcinoma (HCC)\, a low-TMB cancer\nApply the benchmarking results of neoantigen detection performance using HCC-specific variants from COSMIC or DepMap\nTake full advantage of the breadth and accuracy of COSMIC data with downloaded content and other resources\n\nCOSMIC’s scientific and curation team will also answer your questions live during the webinar. \n  \nSpeaker: Kyle Nilson\, PhD \nKyle Nilson\, PhD\, is a sequencing-focused molecular biologist with a background in biochemistry and technical support. As a field software trainer at QIAGEN Digital Insights\, Dr. Nilson works closely with QIAGEN’s global bioinformatics team to provide direct customer support and assist with software training\, implementation\, and optimization. He earned his Ph.D. in molecular and cellular biology from the University of Iowa\, where he studied the regulation of RNA polymerase II transcription and co-transcriptional mRNA processing. Dr. Nilson then completed his postdoctoral training at Penn State and Cornell University\, focusing exclusively on next-generation sequencing method development to study chromatin.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/expanding-neoantigen-discovery-with-cosmic/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
END:VEVENT
END:VCALENDAR